This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

TRxADE HEALTH Temettü

Temettü kriter kontrolleri 0/6

TRxADE HEALTH does not have a record of paying a dividend.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	2.9%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-€2.99
Temettü verim tahmini	n/a

Son temettü güncellemeleri

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: Insufficient data to determine if 4E40's dividends per share have been stable in the past.

Büyüyen Temettü: Insufficient data to determine if 4E40's dividend payments have been increasing.

Piyasaya Karşı Temettü Getirisi

TRxADE HEALTH Piyasaya Karşı Temettü Getirisi

4E40 temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (4E40)	n/a
Pazarın Alt %25'i (DE)	1.6%
Pazarın En İyi %25'i (DE)	4.8%
Sektör Ortalaması (Healthcare Services)	2.9%
Analist tahmini (4E40) (3 yıla kadar)	n/a

Önemli Temettü: Unable to evaluate 4E40's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Yüksek Temettü: Unable to evaluate 4E40's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Insufficient data to calculate 4E40's payout ratio to determine if its dividend payments are covered by earnings.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Unable to calculate sustainability of dividends as 4E40 has not reported any payouts.

This company is no longer active

TRxADE HEALTH Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

TRxADE HEALTH, INC. Announces Special Cash Dividend, Payable on or About July 24, 2024

Recent updates

Scienture Inc. acquired TRxADE HEALTH, Inc. (NasdaqCM:MEDS) in a reverse merger transaction in a transaction valued at $103 Million.

TRxADE HEALTH, INC. Announces Special Cash Dividend, Payable on or About July 24, 2024

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

TRxADE HEALTH, Inc. announced delayed 10-Q filing

TRxADE HEALTH, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

TRxADE HEALTH, Inc. announced delayed annual 10-K filing

Superlatus Foods, Inc. acquired Superlatus, Inc from TRxADE HEALTH, Inc. (NasdaqCM:MEDS) for $0.000001 million.

TRxADE HEALTH Receives Notice from Nasdaq Regarding Non-Compliance with the Timely Filing Requirement for Continued Listing Under Nasdaq Listing Rule 5250(c)(1)

TRxADE HEALTH, Inc. announced delayed 10-Q filing

TRxADE HEALTH, Inc. (NasdaqCM:MEDS) entered into a binding agreement to acquire The Urgent Company, Inc. from Perfect Day, Inc.

TRxADE HEALTH, Inc. to Report Q2, 2023 Results on Aug 14, 2023

TRxADE HEALTH Receives Non-Compliance Notice from Nasdaq

TRxADE HEALTH, Inc. (NasdaqCM:MEDS) entered into a binding letter of intent to acquire Superlatus, Inc.

TRxADE HEALTH, Inc., Annual General Meeting, Jun 15, 2023

TRxADE HEALTH Submits Hearing Request to the Nasdaq Hearings Panel

TRxADE HEALTH Receives A Delist Determination Letter from Nasdaq

Wood Sage, LLC entered into a membership interest purchase agreement to acquire Community Specialty Pharmacy, LLC from TRxADE HEALTH, Inc. (NasdaqCM:MEDS) for $0.1 million.

Wood Sage, LLC entered into Membership Interest Purchase Agreement to acquire Alliance Pharma Solutions, LLC for $0.125 million.

TRxADE HEALTH, INC Announces Board Changes

TRxADE HEALTH Receives Written Notice from Nasdaq

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.061 loss per share (vs US$0.16 loss in 3Q 2021)

TRxADE HEALTH, Inc. to Report Q3, 2022 Results on Nov 07, 2022

No longer forecast to breakeven

TRxADE HEALTH Provides Update on Retaining Compliance Regarding Listing

Less than half of directors are independent

Trxade Health, Inc. Appoints Mr. Jeff Newell to Its Board of Directors, Member of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee

TRxADE HEALTH, Inc. Announces the Resignation of Christine L. Jennings as Member of the Board of Directors

TRxADE HEALTH, Inc. Appoints Jeff Newell to Its Advisory Board

TRxADE HEALTH Receives Non-Compliance Letter from Nasdaq

Second quarter 2022 earnings released: US$0.13 loss per share (vs US$0.32 loss in 2Q 2021)

TRxADE HEALTH, Inc. to Report Q2, 2022 Results on Jul 25, 2022

First quarter 2022 earnings released: US$0.12 loss per share (vs US$0.081 loss in 1Q 2021)

No longer forecast to breakeven

TRxADE HEALTH, Inc. to Report Q1, 2022 Results on May 09, 2022

TRxADE HEALTH, Inc., Annual General Meeting, Jun 02, 2022

TRxADE HEALTH, Inc. Announces Management Changes

Full year 2021 earnings released: US$0.65 loss per share (vs US$0.33 loss in FY 2020)

Third quarter 2021 earnings released: US$0.16 loss per share (vs US$0.017 profit in 3Q 2020)

Second quarter 2021 earnings released: US$0.32 loss per share (vs US$0.072 loss in 2Q 2020)

Independent Director Pamela Tenaerts has left the company

Independent Director Michael Peterson has left the company

Trxade Group, Inc. (NasdaqCM:MEDS) entered into an agreement to acquire QualityCare Pharmacies.

First quarter 2021 earnings released: US$0.081 loss per share (vs US$0.026 profit in 1Q 2020)

Full year 2020 earnings released: US$0.33 loss per share (vs US$0.048 loss in FY 2019)

New 90-day high: €4.96

New 90-day low: €3.98

Third quarter earnings released

Trxade Group, Inc. to Report Q3, 2020 Results on Oct 26, 2020

New 90-day low: €4.18

New 90-day low - €4.76

Trxade Group, Inc. to Report Q2, 2020 Results on Jul 27, 2020

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin